ClinicalTrials.gg
CompletedNCT00500071Updated Mar 10, 2022Results posted

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

A Phase 4 interventional study of Vyvanse (lisdexamfetamine dimesylate) in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Shire. Completed at 46 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2022-03-10.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
318
Allocation
Not applicable
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
6th of 51
318 · median 48
Started
2007
with 2 others
Phase 4
23 of 51
none open now
Registered
5th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 6th largest by enrollment, is one of 3 that started in 2007, is one of 23 in phase 4, and was the 5th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

Assess the efficacy \& tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect.

Read the detailed description

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (lisdexamfetamine dimesylate) in Children aged 6-12 Diagnosed with ADHD

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder (ADHD)
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female aged 6-12 years inclusive at the time of consent.
  2. Females of (FOCP) must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to comply with any applicable requirements of the protocol.
  3. primary diagnosis of ADHD based on a detailed psychiatric evaluation.
  4. Subjects must have a baseline ADHD-RS-IV total score ≥28.
  5. Subject is functioning at an age-appropriate level intellectually.
  6. comply with all the testing and requirements.
  7. Subject is able to swallow a capsule.
  8. Subject has blood pressure measurements within the 95th percentile for age, gender, and height.

Exclusion criteria

Exclusion Criteria

  1. Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder or other symptomatic manifestations.
  2. Subject has Conduct Disorder.
  3. Subject has a documented allergy, , or intolerance to amphetamines.
  4. Subject has failed to respond to one or more adequate courses (dose and duration) of amphetamine therapy.
  5. The subject has a recent history (within the past 6 months) of suspected substance abuse or dependence.
  6. Subject has a positive urine drug result.
  7. Subject weighs less than 50 pounds (22.7kg).
  8. Subject is significantly overweight.
  9. Subject has a history of seizures (exclusive of febrile seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.
  10. Subject has any reported history of abnormal thyroid function.
  11. Subject has taken another product or taken part in a clinical trial within 30 days prior to Screening.
  12. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments.
  13. The female subject is pregnant or lactating.
  14. Subject is well-controlled on their current ADHD medication with acceptable tolerability.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    1

    Drug: Vyvanse (lisdexamfetamine dimesylate)

Interventions

  • Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Score at 7 Weeks

    Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

    Time frame: Baseline and 7 weeks

Secondary outcomes

  1. Weekly Change From Baseline in Total ADHD-RS-IV Score

    Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

    Time frame: Baseline and 1, 2, 3, 4, 5, 6, and 7 weeks

  2. Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 or 2 on the scale.

    Time frame: 7 weeks

  3. Number of Participants With Improvement onParent Global Assessment (PGA)

    Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: 7 weeks

  4. Change From Baseline in Expression and Emotional Scale for Children (EESC) Scores at 7 Weeks

    Expression and Emotional Scale for Children (EESC) consists of 29 items rated on a scale from 1 (not true at all) to 5 (very much true). Lower scores reflect better emotional outcomes.

    Time frame: Baseline and 7 weeks

  5. Changes From Baseline in Behavior Rating Inventory of Executive Function (BRIEF) Scores at 7 Weeks

    Behavior Rating Inventory of Executive Function (BRIEF) is an 86-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Lower scores reflect better functioning.

    Time frame: Baseline and 7 weeks

07

Results

Posted Sep 1, 2009

Participant flow

Screening and Washout Phase
Participant flow — Screening and Washout Phase
MilestoneVyvanse
Started318
Completed317
Not completed1
Withdrew: Protocol violation1
Dose-optimization and Maintenance Phase
Participant flow — Dose-optimization and Maintenance Phase
MilestoneVyvanse
Started317
Completed295
Not completed22
Withdrew: Adverse event13
Withdrew: Protocol violation2
Withdrew: Lack of efficacy2
Withdrew: Withdrawal by subject1
Withdrew: Lack of protocol compliance4
30-day Safety Follow-up
Participant flow — 30-day Safety Follow-up
MilestoneVyvanse
Started295
Completed278
Not completed17
Withdrew: Lost to follow-up17

Outcome measures

SecondaryWeekly Change From Baseline in Total ADHD-RS-IV Score

Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

Time frame:
Baseline and 1, 2, 3, 4, 5, 6, and 7 weeks
Reported as:
Mean · Units on a scale
Weekly Change From Baseline in Total ADHD-RS-IV Score
Units on a scaleVyvanse
Week 1-11.3 ± 0.62
Week 2-17.8 ± 0.63
Week 3-21.7 ± 0.61
Week 4-25.4 ± 0.61
Week 5-27.0 ± 0.60
Week 6-28.9 ± 0.60
Week 7-29.8 ± 0.58
Statistical analysis
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001
PrimaryChange From Baseline in Total Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Score at 7 Weeks

Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

Time frame:
Baseline and 7 weeks
Reported as:
Mean · Units on a scale
Change From Baseline in Total Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Score at 7 Weeks
Units on a scaleVyvanse
Change From Baseline in Total Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Score at 7 Weeks-28.6 ± 0.61
Statistical analysis
  • Vyvanse · t-test, 1 sided · p = < 0.0001
SecondaryNumber of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 or 2 on the scale.

Time frame:
7 weeks
Reported as:
Number · Participants
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)
ParticipantsVyvanse
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)284
SecondaryNumber of Participants With Improvement onParent Global Assessment (PGA)

Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
7 weeks
Reported as:
Number · Participants
Number of Participants With Improvement onParent Global Assessment (PGA)
ParticipantsVyvanse
Number of Participants With Improvement onParent Global Assessment (PGA)267
SecondaryChange From Baseline in Expression and Emotional Scale for Children (EESC) Scores at 7 Weeks

Expression and Emotional Scale for Children (EESC) consists of 29 items rated on a scale from 1 (not true at all) to 5 (very much true). Lower scores reflect better emotional outcomes.

Time frame:
Baseline and 7 weeks
Reported as:
Mean · Units on a scale
Change From Baseline in Expression and Emotional Scale for Children (EESC) Scores at 7 Weeks
Units on a scaleVyvanse
Change From Baseline in Expression and Emotional Scale for Children (EESC) Scores at 7 Weeks-7.4 ± 18.3
Statistical analysis
  • Vyvanse · t-test, 1 sided · p = < 0.0001
SecondaryChanges From Baseline in Behavior Rating Inventory of Executive Function (BRIEF) Scores at 7 Weeks

Behavior Rating Inventory of Executive Function (BRIEF) is an 86-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Lower scores reflect better functioning.

Time frame:
Baseline and 7 weeks
Reported as:
Mean · Units on a scale
Changes From Baseline in Behavior Rating Inventory of Executive Function (BRIEF) Scores at 7 Weeks
Units on a scaleVyvanse
Global Executive Composite-17.9 ± 12.5
Behavioral Recognition Index-15.4 ± 12.6
Metacognition Index-17.6 ± 12.3
Statistical analysis
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001
  • Vyvanse · t-test, 1 sided · p = < 0.0001

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vyvanse—2/317 (0.6%)269/317 (84.9%)
Most frequent serious events
Most frequent serious events
EventVyvanse
SyncopeCardiac disorders1/317
Sinus arrestCardiac disorders1/317
Most frequent other events
Most frequent other events
EventVyvanse
Decreased appetiteMetabolism and nutrition disorders137/317
Weight decreasedInvestigations54/317
IrritabilityGeneral disorders51/317
InsomniaNervous system disorders51/317
HeadacheNervous system disorders44/317
Abdominal pain upperGastrointestinal disorders42/317
Initial insomniaNervous system disorders36/317
Affect liabilityPsychiatric disorders23/317
NauseaGastrointestinal disorders17/317
VomitingGastrointestinal disorders17/317

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Vyvanse
<=18 years318
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Vyvanse
Mean9.1 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)Vyvanse
Female93
Male225
Region of Enrollment
Region of Enrollment(Participants)Vyvanse
United States318
08

Study locations

46 sites
  • Melmed Center
    Scottsdale, Arizona, United States
  • Valley Clinical Research
    El Centro, California, United States
  • Peninsula Research Assoc, Inc
    Rolling Hills Estates, California, United States
  • UCSF-Langely Porter Psych Institute
    San Francisco, California, United States
  • Encompass Clinical Research
    Spring Valley, California, United States
  • Shire Clinical Research Site
    Wildomar, California, United States
  • Sarkis Clinical Trials
    Gainesville, Florida, United States
  • Shire Clinical Research Site
    Hialeah, Florida, United States
  • CNS Research Institute, Inc
    Jacksonville, Florida, United States
  • CORE Research, Inc
    Maitland, Florida, United States
  • Miami Research Associates
    Miami, Florida, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida, United States
  • Children's Development Center
    Winter Park, Florida, United States
  • Capstone Clinical Research
    Libertyville, Illinois, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana, United States
  • Shire Clinical Research Site
    Terre Haute, Indiana, United States
  • Shire Clinical Research Site
    Newton, Kansas, United States
  • Psychiatric Associates
    Overland Park, Kansas, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky, United States
  • Shire Clinical Research Site
    Lexington, Kentucky, United States
  • Pedia Research
    Owensboro, Kentucky, United States
  • Four Rivers Clinical Research, Inc.
    Paducah, Kentucky, United States
  • Shire Clinical Research Site
    Troy, Michigan, United States
  • University of Rochester, School of Medicine and Dentistry
    Rochester, New York, United States
  • Piedmont Neuropsychiatry
    Charlotte, North Carolina, United States
  • University Commons Office Park
    Durham, North Carolina, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio, United States
  • BHI, Inc.
    Moore, Oklahoma, United States
  • Shire Clinical Research Site
    Oklahoma City, Oklahoma, United States
  • Oregon Center for Clinical Investigations, Inc
    Eugene, Oregon, United States
  • Oregon Center For Clinical Investigations, Inc.
    Portland, Oregon, United States
  • Summit Research Network
    Portland, Oregon, United States
  • Oregon Center for Clinical Investigations, Inc.
    Salem, Oregon, United States
  • ADHD Program, Western Psychiatric Institute and Clinic
    Pittsburgh, Pennsylvania, United States
  • The Jackson Clinic
    Jackson, Tennessee, United States
  • Clinical Neuroscience Solutions, Inc
    Memphis, Tennessee, United States
  • FutureSearch Trials
    Austin, Texas, United States
  • Claghorn-Lesem Research Clinic Inc.
    Bellaire, Texas, United States
  • Red Oak Psychiatry Associates P.A.
    Houston, Texas, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas, United States
  • ADHD Clinic of San Antonio
    San Antonio, Texas, United States
  • NeuroScience, Inc
    Herndon, Virginia, United States
  • Dominion Clinical Research
    Midlothian, Virginia, United States
  • International Clinical Research Associates, LLC
    Richmond, Virginia, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington, United States
09

References and documents

Publications

  • Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009 Dec;19(6):649-62. doi: 10.1089/cap.2008.0165. PubMed 20035583 ↗
  • Katic A, Ginsberg L, Jain R, Adeyi B, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Turgay A, Findling RL. Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate. J Atten Disord. 2012 Jul;16(5):384-97. doi: 10.1177/1087054710389990. Epub 2010 Dec 20. PubMed 21173426 ↗
  • Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Findling RL. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. J Child Adolesc Psychopharmacol. 2010 Dec;20(6):503-11. doi: 10.1089/cap.2009.0110. PubMed 21186969 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2007 to primary completion in Jan 2008, 6 months.

Results were first posted in Sep 2009, 1 year 7 months after primary completion.

Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2007
First posted
Jul 12, 2007
StartActual
Jun 28, 2007
Primary completionActual
Jan 2, 2008
CompletionActual
Jan 2, 2008
Results first posted
Sep 1, 2009
Last update
Mar 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00500071
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 12, 2007
Start date
Jun 28, 2007
Primary completion
Jan 2, 2008
Completion
Jan 2, 2008
Results posted
Sep 1, 2009
Last update
Mar 10, 2022

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion